Univercells Technologies by Donaldson has launched the scale-X™ nexo bioreactor, a breakthrough in fixed-bed bioreactor design, helping lab managers optimize early-stage cell culture processes. With a 0.5 m² growth surface, the scale-X nexo enables labs to achieve high cell densities and consistent distribution, enhancing efficiency in cell and gene therapy and vaccine development. The scale-X nexo’s scalability ensures labs can quickly transition from development to commercial production while maintaining cost efficiency.
How scale-X nexo Benefits Lab Managers
- Efficient Resource Use: Reduced media and reagent consumption for lower operational costs.
- Direct Scalability: Simplifies the scale-up process with a pathway to larger scale-X bioreactors.
- Time Savings in Development: Optimized for rapid setup and efficient process screening.
- Enhanced Monitoring: Skaia™ software estimates cell count without sampling, boosting productivity.
With its low-cost, low-volume approach, the scale-X nexo bioreactor allows lab managers to efficiently manage costs, ensuring sustainable, high-density cell cultures for biopharma applications.
This article is an AI generated summary of a published press release provided by Univercells Technologies
